Jaguar Animal Health Inc (NASDAQ:JAGX) – Investment analysts at Feltl & Co. lifted their FY2016 earnings estimates for shares of Jaguar Animal Health in a note issued to investors on Thursday. Feltl & Co. analyst B. Haynor now forecasts that the brokerage will earn ($1.42) per share for the year, up from their prior forecast of ($1.56). Feltl & Co. also issued estimates for Jaguar Animal Health’s Q4 2016 earnings at ($0.35) EPS, FY2017 earnings at ($1.33) EPS and FY2018 earnings at ($0.20) EPS.

Separately, Zacks Investment Research downgraded Jaguar Animal Health from a “buy” rating to a “hold” rating in a research note on Wednesday, August 10th.

Shares of Jaguar Animal Health (NASDAQ:JAGX) opened at 0.6709 on Monday. The company’s 50-day moving average price is $0.94 and its 200-day moving average price is $1.40. The stock’s market cap is $7.46 million. Jaguar Animal Health has a 52-week low of $0.67 and a 52-week high of $4.60.

About Jaguar Animal Health

Jaguar Animal Health, Inc is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products.

5 Day Chart for NASDAQ:JAGX

Receive News & Stock Ratings for Jaguar Animal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc and related stocks with our FREE daily email newsletter.